Zoetis Bolsters Precision Diagnostics with Strategic Genomics Acquisition

Zoetis buys Neogen's GeneSeek genomics unit for $160M, enhancing its predictive analytics in animal health. The deal highlights diverging strategies for both firms.

In a decisive move to expand its capabilities in data-driven veterinary medicine, Zoetis has announced the acquisition of a key genomics business. The animal health leader is purchasing the genomics unit of Neogen, known as GeneSeek, for a total of $160 million.

Strengthening Predictive Insights

The definitive agreement, disclosed on Monday, will see Zoetis integrate a global operation with five laboratories serving clients across more than 120 countries. GeneSeek is recognized as a market leader in the US cattle and dairy livestock sector. Jamie Brannan, Zoetis's Chief Commercial Officer, emphasized that the acquisition is fundamentally about enhancing the company's capacity to deliver predictive analytics. The strategic goal is to leverage data-driven innovation for more efficient and proactive animal healthcare.

For its 2025 fiscal year, the GeneSeek segment generated approximately $90 million in revenue.

Diverging Corporate Strategies

This transaction highlights two distinct corporate paths. While Zoetis uses the purchase to grow its diagnostic footprint, Neogen is streamlining its portfolio. According to Neogen CEO Mike Nassif, the divestiture follows a portfolio review. The company plans to use the net proceeds primarily for debt reduction, allowing it to sharpen its focus on its own core markets.

Zoetis approaches this deal from a position of financial strength. The company recently reported fourth-quarter 2025 earnings of $1.48 per share, surpassing analyst expectations. This solidity is reflected in its shareholder base, with over 92% of shares held by institutional investors. Notably, Norges Bank recently established a new position valued at around $810 million. On the stock market, Zoetis shares are trading steadily at €109.26, though this price remains about 32% below its 52-week high.

Timeline and Shareholder Returns

Pending the receipt of customary regulatory approvals, the acquisition is expected to be finalized in the second half of 2026. For shareholders, a nearer-term event is on the calendar: the next quarterly dividend of $0.53 per share is scheduled for payout on June 2, 2026. This commitment to shareholder returns continues despite the company's ongoing investment activities.